 "Aurobindo Pharma")
Aurobindo Pharma’s French subsidiary, Arrow Generiques SAS, has signed an agreement to buy select calcium and vitamin D3 commercial products from Teva in France. Arrow Generiques will acquire the right, title and interest in calcium and calcium-vitamin D3 products, including the use of the Orocal trademark.
The transaction is subject to the approval of the European Commission. Following receipt of clearances from European authorities, Arrow Generiques will integrate these products with its existing commercial operations in France, and focus on maximising their potential. Arrow Generiques and Teva intend to ensure continuity of the supply of the products to the market.
This acquisition will enable Aurobindo Pharma’s French arm to continue to increase its branded products portfolio and leverage its position as a key player in the drug market. Arrow Generiques is a pharmaceutical company with focus on selling generics on the retail and hospital markets in France since 2002. Arrow Generiques entered a strategy of diversification with the acquisition of the first branded products a few years ago to become a company balanced between generics, branded products & biosimilars on retail and hospital markets. A dedicated business unit with sales and marketing team had been set up to specifically enhance this business.
“Arrow Generiques has continued developing the brand awareness among prescribers through the promotion of mature products and the launch of specialties for patients care. The achievement of the medical visit certification confirms the company's strategy in medical promotion. This deal will boost the position of Arrow Generiques and open new opportunities for the future,” said Aurobindo Pharma in a press release.
